Placebo News and Research

RSS

Ketamine's antidepressant effects involve the brain's opioid system

Ketamine is a highly effective, fast-acting antidepressant that works even for patients who have not responded to other medications.

24 Jul 2025

What happens to your weight after quitting GLP-1 anti-obesity drugs?

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six months. Despite this rebound, most patients maintain some weight loss compared to baseline a year after discontinuation.

23 Jul 2025

Chinese study shows lasting weight loss after tirzepatide treatment

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

23 Jul 2025

Novel DNA plasmid therapy shows high success rate in treating chronic pain in dogs

Elenagen™, a novel DNA plasmid therapy that previously demonstrated high clinical benefit and low toxicity in cancer patients, has now shown significant promise in alleviating chronic pain demonstrating a 90% success rate.

23 Jul 2025

Oral microbiome changes explain blood pressure reduction from beetroot juice

The blood pressure lowering effect of nitrate-rich beetroot juice in older people may be due to specific changes in their oral microbiome, according to the largest study of its kind.

23 Jul 2025

Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide significant benefits for cardiovascular, kidney, liver, joint, and sleep-related diseases. These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.

22 Jul 2025

Date vinegar lowers blood sugar and cholesterol in type 2 diabetes

This study reveals that red date vinegar intake improves blood glucose and lipid profiles in type 2 diabetes, indicating potential for metabolic risk reduction.

22 Jul 2025

Weight regain observed in patients after ending obesity drug treatment

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, finds a meta-analysis published in BMC Medicine.

22 Jul 2025

Gluten may not be the culprit for many people with irritable bowel syndrome

A new study from McMaster University researchers has found that many people with irritable bowel syndrome (IBS) who believe they are sensitive to gluten or wheat may not actually react to these ingredients.

22 Jul 2025

Research highlights guselkumab's impact on Crohn's endoscopic healing

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed an established standard of care in promoting intestinal healing and symptom relief.

18 Jul 2025

New review identifies promising and under-researched OTC depression aids

Most people have heard of St John's Wort and omega-3s. But did you know there are a lot more over-the-counter herbal products and supplements out there targeting depression? In our review of clinical trials of these products, we found 64 different over-the-counter (OTC) products that have been evaluated for depression – but with differing levels of evidence for each.

16 Jul 2025

UNM researchers get $1 million grant to launch early clinical trial for Alzheimer’s vaccine

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to clear pathological tau protein from the brains of patients suffering from Alzheimer's dementia.

15 Jul 2025

Tirzepatide reduces obesity-associated breast cancer growth in mouse model

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025

Monoclonal antibody delivered through the nose blocks hay fever in mice

Approximately 40% of the European population are allergic to pollen, and their symptoms cause an estimated loss of 100 million school- and workdays every year.

11 Jul 2025

Combination therapy sets new survival standard for advanced biliary tract cancer

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the first-line treatment for people with advanced biliary tract cancer (aBTC), researchers have shown that after three years more than twice as many study participants treated with durvalumab plus GemCis had survived compared to those treated with a placebo plus GemCis.

10 Jul 2025

New analysis shows stopping antidepressants rarely leads to severe symptoms

The largest review of 'gold standard' antidepressant withdrawal studies to date has identified the type and incidence of symptoms experienced by people discontinuing antidepressants, finding most people do not experience severe withdrawal.

10 Jul 2025

Brain stimulation and coaching help older adults increase physical activity

A study published in The Journals of Gerontology: Series A reports that a novel combination of brain stimulation and personalized coaching significantly increased physical activity in older adults and held steady for months.

8 Jul 2025

Tirzepatide tops the charts for blood sugar and weight loss in type 2 diabetes

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose control and weight loss, while liraglutide offered the lowest hypoglycemia risk.

7 Jul 2025

Illness expectations play a crucial role in asthma progression and patient-reported outcomes

Individual expectations about one's health can influence him/her future condition and the speed of the progression of a disease: in fact, a research conducted by researchers of psychology at the Università Cattolica del Sacro Cuore, Milan campus, shows that, after a diagnosis of asthma, people who are optimistic about their health will have a slower progression of the disease.

3 Jul 2025

Long-term study confirms lasting benefits of lifestyle changes in preventing diabetes

In the early 2000s the U.S. Diabetes Prevention Program (DPP), a large randomized clinical trial, showed that intensive lifestyle modification was better than a medication called metformin at preventing at-risk patients from developing Type 2 diabetes.

3 Jul 2025